









市场行情
/
股票
/
nasdaq-cccc
/

C4 Therapeutics Inc

CCCC

2.140USD

-0.050-2.28%

收盘 01/09, 16:00（美东）报价延迟15分钟

158.73M总市值

亏损市盈率 TTM



C4 Therapeutics Inc

2.140

-0.050-2.28%

概览公司财务分析

概览

公司

财务

分析

关于 C4 Therapeutics Inc 公司

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

C4 Therapeutics Inc简介



公司代码CCCC

公司名称C4 Therapeutics Inc

上市日期Oct 02, 2020

CEOHirsch (Andrew J)

员工数量110

证券类型Ordinary Share

年结日Oct 02

公司地址490 Arsenal Way

城市WATERTOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02472

电话16172310700

网址https://c4therapeutics.com/

公司代码CCCC

上市日期Oct 02, 2020

CEOHirsch (Andrew J)

C4 Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Kendra Adams

Chief Financial Officer, Treasurer

168.59K

+3475.00%

Dr. Paige Mahaney, Ph.D.

Chief Scientific Officer

118.56K

+13556.00%

Dr. Scott N. Boyle, Ph.D.

Chief Business Officer

107.81K

+51238.00%

Mr. Utpal Koppikar

Independent Director

5.67K

Dr. Kenneth C. (Ken) Anderson, M.D.

Independent Director, Co-Founder

Mr. Andrew J. Hirsch

President, Chief Executive Officer, Director

Ms. Jolie M. Siegel, J.D.

Chief Legal Officer, Corporate Secretary

Ms. Kelly A. Schick

Chief People Officer

Dr. Laura Bessen, M.D.

Independent Director

Dr. Donna Grogan, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Ms. Kendra Adams

Chief Financial Officer, Treasurer

168.59K

+3475.00%

Dr. Paige Mahaney, Ph.D.

Chief Scientific Officer

118.56K

+13556.00%

Dr. Scott N. Boyle, Ph.D.

Chief Business Officer

107.81K

+51238.00%

Mr. Utpal Koppikar

Independent Director

5.67K

Dr. Kenneth C. (Ken) Anderson, M.D.

Independent Director, Co-Founder

Mr. Andrew J. Hirsch

President, Chief Executive Officer, Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

Point72 Asset Management, L.P.

8.75%

RA Capital Management, LP

8.25%

Lynx1 Capital Advisors LLC

7.32%

Soleus Capital Management, L.P.

7.28%

OrbiMed Advisors, LLC

5.40%

其他

62.99%

持股股东

占比

Point72 Asset Management, L.P.

8.75%

RA Capital Management, LP

8.25%

Lynx1 Capital Advisors LLC

7.32%

Soleus Capital Management, L.P.

7.28%

OrbiMed Advisors, LLC

5.40%

其他

62.99%

股东类型

持股股东

占比

Hedge Fund

24.96%

Investment Advisor

17.54%

Venture Capital

8.41%

Investment Advisor/Hedge Fund

8.15%

Research Firm

7.96%

Private Equity

5.40%

Corporation

5.03%

Individual Investor

2.44%

Pension Fund

0.09%

其他

20.01%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

295

70.29M

72.52%

+1.58M

2025Q3

308

52.96M

108.83%

-2.15M

2025Q2

306

55.08M

118.23%

-10.19M

2025Q1

320

64.50M

110.39%

-13.86M

2024Q4

320

64.84M

109.43%

+173.51K

2024Q3

315

64.67M

104.71%

+3.40M

2024Q2

309

61.26M

103.56%

+2.76M

2024Q1

313

58.50M

89.36%

-2.80M

2023Q4

309

47.27M

101.07%

+10.16M

2023Q3

305

34.95M

100.17%

+181.16K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Point72 Asset Management, L.P.

8.48M

8.75%

+8.48M

Oct 17, 2025

RA Capital Management, LP

8.00M

8.25%

+8.00M

Oct 17, 2025

Lynx1 Capital Advisors LLC

7.10M

7.32%

Sep 30, 2025

Soleus Capital Management, L.P.

7.05M

7.28%

+75.00K

+1.07%

Sep 30, 2025

OrbiMed Advisors, LLC

5.24M

5.4%

-1.60M

-23.35%

Sep 30, 2025

Betta investment Hong Kong Ltd

4.87M

5.03%

-693.38K

-12.45%

Apr 22, 2025

Morgan Stanley & Co. LLC

4.86M

5.02%

+1.71M

+54.22%

Sep 30, 2025

Wasatch Global Investors Inc

4.85M

5.01%

-2.57M

-34.64%

Sep 30, 2025

The Vanguard Group, Inc.

3.19M

3.29%

+173.53K

+5.75%

Sep 30, 2025

BofA Global Research (US)

2.05M

2.12%

+45.16K

+2.25%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.03%

Fidelity Enhanced Small Cap ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

ProShares Ultra Nasdaq Biotechnology

0.02%

Invesco Nasdaq Biotechnology ETF

0.02%

iShares Biotechnology ETF

0.01%

Avantis US Small Cap Equity ETF

0.01%

ProShares Hedge Replication ETF

iShares Russell 2000 Value ETF

iShares Core S&P Total U.S. Stock Market ETF

iShares Micro-Cap ETF

占比0.03%

Fidelity Enhanced Small Cap ETF

占比0.02%

Invesco RAFI US 1500 Small-Mid ETF

占比0.02%

ProShares Ultra Nasdaq Biotechnology

占比0.02%

Invesco Nasdaq Biotechnology ETF

占比0.02%

iShares Biotechnology ETF

占比0.01%

Avantis US Small Cap Equity ETF

占比0.01%

ProShares Hedge Replication ETF

占比0%

iShares Russell 2000 Value ETF

占比0%

iShares Core S&P Total U.S. Stock Market ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

C4 Therapeutics Inc的前五大股东是谁？



C4 Therapeutics Inc 的前五大股东如下：
Point72 Asset Management, L.P.持有股份：8.48M，占总股份比例：8.75%。
RA Capital Management, LP持有股份：8.00M，占总股份比例：8.25%。
Lynx1 Capital Advisors LLC持有股份：7.10M，占总股份比例：7.32%。
Soleus Capital Management, L.P.持有股份：7.05M，占总股份比例：7.28%。
OrbiMed Advisors, LLC持有股份：5.24M，占总股份比例：5.40%。